Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or I...
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combina...
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebuli...
Bionic Pancreas in CFRD
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using...
Ensuring Access to Optimal Therapy in CF: The ENACT Study
This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ab...
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection....
Study With Phage for CF Subjects With Pseudomonas Lung Infection
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twi...
BEGIN Novel ImagiNG Biomarkers
To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe)....
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tol...
4D-710 in Adult Patients With Cystic Fibrosis
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis....
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that char...
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation...
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy....
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to ...
Top Cities for Cystic Fibrosis Clinical Trials
Cystic Fibrosis clinical trials are recruiting across 46 cities. Here are the cities with the most active studies:
About Cystic Fibrosis
Cystic fibrosis is a genetic disorder that causes thick, sticky mucus to build up in the lungs, digestive tract, and other organs. It is caused by mutations in the CFTR gene. CFTR modulator therapies have dramatically improved outcomes, along with airway clearance techniques and nutritional support.
Clinical trials are advancing new treatments for cystic fibrosis. Currently, 14 studies are recruiting a combined 1,706 participants across the United States. Research is being conducted by 14 organizations including Chris Goss, Vertex Pharmaceuticals Incorporated, Verona Pharma plc and 11 others.
2026 Cystic Fibrosis Research Landscape
As of March 2026, the cystic fibrosis clinical trial landscape includes 14 actively recruiting studies across 46 cities in the United States. These studies are collectively seeking 1,706 participants, with an average enrollment target of 122 per study.
Research is being led by 14 different organizations, including Chris Goss, Vertex Pharmaceuticals Incorporated, Verona Pharma plc, Jaeb Center for Health Research, Arkansas Children's Hospital Research Institute, and 9 others. The large number of sponsors reflects significant research interest and investment in cystic fibrosis treatment advancement.
Geographically, cystic fibrosis trials are most concentrated in Boston, Massachusetts (7 trials); Kansas City, Missouri (6 trials); Birmingham, Alabama (5 trials); Palo Alto, California (4 trials); Denver, Colorado (4 trials) and 7 other cities.
Featured Cystic Fibrosis Studies
Highlighted recruiting studies for cystic fibrosis, selected by enrollment size and research scope.
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmo...
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
Frequently Asked Questions About Cystic Fibrosis Clinical Trials
Are there cystic fibrosis clinical trials near me?
Yes, there are 14 cystic fibrosis clinical trials currently recruiting across 46+ cities in the United States, including Boston, Massachusetts; Kansas City, Missouri; Birmingham, Alabama. Browse the studies above to find one at a location convenient for you.
How do I join a cystic fibrosis clinical trial?
To join a cystic fibrosis clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are cystic fibrosis clinical trials free?
Yes, participation in cystic fibrosis clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of cystic fibrosis treatments are being studied?
Current cystic fibrosis clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 14 research organizations.
Is it safe to participate in cystic fibrosis clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov